Food and Drug Administration

Joint meeting of the

Transmissible Spongiform Encephalopathies Advisory Committee
and the
Blood Products Advisory Committee

January 17, 2002


FDA Final Guidance "Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products," Dorothy Scott, MD, FDA   ppt   htm

Effectiveness of measures taken to protect humans from food-borne exposure to the BSE agent: Implications for risk of variant Creutzfeldt-Jakob disease and blood safety, David M Asher, MD, CBER, FDA   ppt   htm

Variant CJD, An Update, Dr Hester Ward, National CJD Surveillance Centre, UK   ppt   htm

Food chain Protection in the UK, Peter Soul,  Department for Environment, Food and Rural Affairs   ppt  htm

Efforts and needs for global control of BSE and vCJD, Marua N Ricketts MD, MHSc, FRCPC, WHO, CDS, CSR, EPH  ppt   htm

Evaluation of the Potential for BSE in the United States, George M Gray PhD and Joshua Cohen PhD, Harvard School of Public Health, Boston   ppt  htm

Open Public Hearing (Posted 04/04/02)

Statement from the New York Blood Center   pdf

America's Blood Centers, Celso Bianco, MD  pdf

National Hemophilia Foundation   pdf

Alpha-1 Foundation, Miriam O'Day   pdf